In the last 12 months, insiders at Atrium Therapeutics, Inc. ($RNA) filed 17 transactions with the SEC: 0 open-market purchases totaling $0 and 0 sales totaling $0. Net insider sentiment: neutral.
Atrium Therapeutics, Inc. operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- Winslow Brendan R. (Chief Financial Officer) — 2 transactions totaling $0
- Younis Husam (Chief Scientific Officer) — 2 transactions totaling $0
- Flanagan W. Michael (Not found) — 1 transaction totaling $0
- Gallagher Kathleen P. (See Remarks) — 2 transactions totaling $0
- Hoyos Rocio Martin (Chief Strategy Officer) — 2 transactions totaling $0
View all SEC Filings for Atrium Therapeutics, Inc. (RNA).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| April 20, 2026 | Younis Husam | Chief Scientific Officer | A | Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 0 | 9999.99% | 0.00% |
| April 20, 2026 | Gallagher Kathleen P. | See Remarks | A | Common Stock | 102500 | $0.00 | 131,361.0000 | 0 | 355.15% | 0.00% |
| April 20, 2026 | Gallagher Kathleen P. | See Remarks | A | Stock Option (Right to Buy) | 205000 | $0.00 | 205,000.0000 | 0 | 9999.99% | 0.00% |
| April 20, 2026 | Hoyos Rocio Martin | Chief Strategy Officer | A | Common Stock | 30000 | $0.00 | 46,660.0000 | 0 | 180.07% | 0.00% |
| April 20, 2026 | Hoyos Rocio Martin | Chief Strategy Officer | A | Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 0 | 9999.99% | 0.00% |
| April 20, 2026 | Younis Husam | Chief Scientific Officer | A | Common Stock | 30000 | $0.00 | 52,657.0000 | 0 | 132.41% | 0.00% |
| April 20, 2026 | Kenney Stephanie | See Remarks | A | Common Stock | 30000 | $0.00 | 35,460.0000 | 0 | 549.45% | 0.00% |
| April 20, 2026 | Kenney Stephanie | See Remarks | A | Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 0 | 9999.99% | 0.00% |
| April 20, 2026 | Hughes Steven George | Chief Medical Officer | A | Common Stock | 30000 | $0.00 | 73,097.0000 | 0 | 69.61% | 0.00% |
| April 20, 2026 | Hughes Steven George | Chief Medical Officer | A | Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 0 | 9999.99% | 0.00% |
| April 20, 2026 | Winslow Brendan R. | Chief Financial Officer | A | Common Stock | 30000 | $0.00 | 43,601.0000 | 0 | 220.57% | 0.00% |
| April 20, 2026 | Winslow Brendan R. | Chief Financial Officer | A | Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 27, 2026 | BOESS CARSTEN | Not found | A | Stock Option (Right to Buy) | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 27, 2026 | WILSON TROY EDWARD | Not found | A | Stock Option (Right to Buy) | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 27, 2026 | Flanagan W. Michael | Not found | A | Stock Option (Right to Buy) | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 27, 2026 | Skerjanec Simona | Not found | A | Stock Option (Right to Buy) | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 27, 2026 | Boyce Sarah | Not found | A | Stock Option (Right to Buy) | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |